Abstract
FK506-binding proteins have been implicated in numerous human diseases suggesting novel therapeutic opportunities. In particular, the large FKBP51 has emerged as an important regulator of the stress-coping system and as an established risk factor for stress-related disorders. The principal druggabilty of FKBPs is evidenced by the prototypical high affinity ligands FK506 and rapamycin but the development of more refined and selective chemical probes for FKBPs has been challenging. In this review we summarize recent advances in the development of FKBP ligands, which cumulated in the first highly selective ligands for FKBP51. The best ligand SAFit2 allowed the proof-of-concept in mice for FKBP51 inhibitors as potentially novel antidepressants. Finally, we discuss pending issues that need to be addressed for the further development of FKBP51-directed drugs.
Keywords: Antidepressants, FKBP ligand, FKBP51-directed drugs, FK506-binding proteins, homology, therapeutic.
Current Molecular Pharmacology
Title:Recent Progress in FKBP Ligand Development
Volume: 9
Author(s): Xixi Feng, Sebastian Pomplun and Felix Hausch
Affiliation:
Keywords: Antidepressants, FKBP ligand, FKBP51-directed drugs, FK506-binding proteins, homology, therapeutic.
Abstract: FK506-binding proteins have been implicated in numerous human diseases suggesting novel therapeutic opportunities. In particular, the large FKBP51 has emerged as an important regulator of the stress-coping system and as an established risk factor for stress-related disorders. The principal druggabilty of FKBPs is evidenced by the prototypical high affinity ligands FK506 and rapamycin but the development of more refined and selective chemical probes for FKBPs has been challenging. In this review we summarize recent advances in the development of FKBP ligands, which cumulated in the first highly selective ligands for FKBP51. The best ligand SAFit2 allowed the proof-of-concept in mice for FKBP51 inhibitors as potentially novel antidepressants. Finally, we discuss pending issues that need to be addressed for the further development of FKBP51-directed drugs.
Export Options
About this article
Cite this article as:
Feng Xixi, Pomplun Sebastian and Hausch Felix, Recent Progress in FKBP Ligand Development, Current Molecular Pharmacology 2016; 9 (1) . https://dx.doi.org/10.2174/1874467208666150519113313
DOI https://dx.doi.org/10.2174/1874467208666150519113313 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Current Alzheimer Research α2-Adrenoceptors Enhance Cell Proliferation and Mammary Tumor Growth Acting Through both the Stroma and the Tumor Cells
Current Cancer Drug Targets The Novel Multi-Target Iron Chelator, M30 Modulates HIF-1α-Related Glycolytic Genes and Insulin Signaling Pathway in the Frontal Cortex of APP/PS1 Alzheimer’s Disease Mice
Current Alzheimer Research Tumor Specific Novel Taxoid-Monoclonal Antibody Conjugates
Current Medicinal Chemistry Microglial Integrity is Maintained by Erythropoietin Through Integration of Akt and Its Substrates of lycogen Synthase Kinase-3β, β-Catenin, and Nuclear Factor-κB
Current Neurovascular Research Role of Advanced Glycation End Products in Diabetic Neuropathy
Current Pharmaceutical Design Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Emerging Therapeutic Targets and Agents for Glioblastoma Migrating Cells
Anti-Cancer Agents in Medicinal Chemistry Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Tumor Bone Diseases: Molecular Mechanisms and Opportunities for Novel Treatments
Current Medicinal Chemistry - Anti-Cancer Agents Neurokinin-1 Receptor Antagonists as Anticancer Drugs
Letters in Drug Design & Discovery Radiopharmaceutical: Revolutionary Agents for Diagnosis
Current Radiopharmaceuticals Marine Depsipeptides as Promising Pharmacotherapeutic Agents
Current Protein & Peptide Science Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Neuroinflammation and Neuroprotection: An Update on (Future) Neurotrophin-Related Strategies in Multiple Sclerosis Treatment
Current Medicinal Chemistry The PI3K-AKt-mTOR Pathway and New Tools to Prevent Acquired Hormone Resistance in Breast Cancer
Current Pharmaceutical Biotechnology Pharmacologic Evidence of Green Tea in Targeting Tyrosine Kinases
Current Reviews in Clinical and Experimental Pharmacology ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma
Current Medicinal Chemistry Heme Oxygenase -1 Gene Therapy: Recent Advances and Therapeutic Applications
Current Gene Therapy Pre-feasibility Study for Establishing Radioisotope and Radiopharmaceutical Production Facilities in Developing Countries
Current Radiopharmaceuticals